Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare

FLORHAM PARK, N.J., January 4, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today confirmed that it has entered into an exclusive U.S. strategic commercialization agreement with BioCellgraft, Inc. (“BioCellgraft”) under which Celularity will manufacture advanced biomaterial products for BioCellgraft which BioCellgraft will distribute in the United States for use in multiple dental/oral healthcare applications. A copy of BioCellgraft’s announcement of the agreement can be accessed here: https://www.prweb.com/releases/biocellgraft-finalizes-commercialization-agreement-with-celularity-for-the-manufacture-and-distribution-of-products-for-therapeutic-use-in-oral-healthcare-302025082.html. 

Robert J. Hariri, M.D., Ph.D., Chairman, Chief Executive Officer, and founder of Celularity said, “This commercialization agreement with BioCellgraft opens an important pathway for Celularity-manufactured, BioCellgraft-branded and marketed advanced biomaterial products into dental and oral healthcare applications in the United States that include periodontology, implant dentistry and oral surgery, all of which are large and growing markets.” 

Forward-Looking Statements 

This press release includes “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995, as well as within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “might,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “target,” “will,” “would” and the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. The forward-looking statements in this press release include statements regarding The Company’s ability to sufficiently capitalize itself through cash flow from its manufactured biomaterial products, technical operations expertise, and cell banking activities, among others. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including but not limited to: the regulatory status of its biomaterial products; the Company’s ability to develop and maintain sales and marketing capabilities, whether alone or with potential future collaborators; the risks associated with the Company’s current liquidity as well as developments relating to the Company’s competitors and industry, along with those risk factors set forth under the caption “Risk Factors” in The Company’s annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 31, 2023, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that The Company does not presently know, or that The Company currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect The Company’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing the Company’s views as of any subsequent date, and the Company undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.